French pharmaceutical company Ipsen on Wednesday said it has expanded the current distribution agreement for Dysport, with partner Galderma, in aesthetic indications to some Asia-Pacific territories. 6 January 2016
Ireland-incorporated Perrigo has said it will acquire a portfolio of generic dosage forms and strengths of Retin-A (tretinoin) from Matawan Pharmaceuticals, a subsidiary of Rouses Point Pharmaceuticals. 18 December 2015
Canadian drug maker Valeant Pharmaceuticals has struck a deal with the biggest pharmacy chain in the US to sell its skin and eye medications at a discounted price. 16 December 2015
Pharma companies looking to developing innovative treatments from natural products will be given access to the world’s largest private collection of plants thanks to a unique project launched by French company Pierre Fabre. 8 December 2015
The German Institute for Quality and Efficiency in Health Care (IQWiG), in a second dossier assessment of Swiss pharma giant Roche’s cancer drug Perjeta (pertuzumab) resulted in a survival advantage for certain patients taking the drug and hence for a hint of a major added benefit. 4 December 2015
India-based Vyome Biosciences plans a regulatory filing by the end of the year with US Food and Drug Administration for its lead molecule (VB 1953), which targets the vast drug resistant acne prescription market, co-founder and chief executive N Venkat told The Pharma Letter in an exclusive interview. 30 November 2015
In another acquisition move, Spain’s largest pharma company Almirall has signed an agreement to acquire 100% of the share capital of the Switzerland-headquartered Poli Group Holdings. 30 November 2015
UK specialty drugmaker Alliance Pharma has entered into a conditional agreement with Sinclair IS Pharma to acquire certain assets and businesses principally focused on dermatology. 26 November 2015
Spanish pharma company Almirall has bought the rights to two dermatology products from Stiefel – a GSK affiliate - in exchange for distribution rights to Toctino (alitretinoin) and an undisclosed cash payment, it has been announced. 23 November 2015
Japan’s Taiho Pharmaceutical has submitted an application for approval of the manufacture and marketing of TAC-202 (bilastine), an oral anti-allergy drug, to the Japanese Ministry of Health, Labor and Welfare. 16 November 2015
Derma Sciences is to stop development of its drug aclerastide for diabetic foot ulcer healing following the advice of a Data Monitoring Committee (DMC). 13 November 2015
LEO Pharma has entered into an asset purchase agreement under which Japanese drug major Astellas Pharma will transfer its global dermatology business to LEO. 11 November 2015
New market research titled "EpiCast Report: Atopic Dermatitis - Epidemiology Forecast to 2024" says atopic dermatitis therapeutic sales in the nine major markets (9MM) are forecast to increase to $5.6 billion by 2022, at a compound annual growth rate (CAGR) of 3.8%. 11 November 2015
Spain’s largest pharma company Almirall today announced year-to-date financial results, showing that total revenues for the first nine months of 2015 were 595.3 million euros ($640.8 million). 9 November 2015
LEO Pharma said today that its Enstilar (calcipotriene/betamethasone dipropionate) foam has been approved by the US Food and Drug Administration for the topical treatment of plaque psoriasis in adults 18 years of age and older. 19 October 2015
US pharma giant Pfizer says it has received a complete response letter from the US Food and Drug Administration for its supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib citrate) for the treatment of adult patients with moderate to severe chronic plaque psoriasis. 15 October 2015
US biotech firm Celgene Corp via its unit Celgene International Sàrl, said its Otezla (apremilast), to treat plaque psoriasis has shown meaningful improvements. 13 October 2015
The US Food and Drug Administration (FDA) has accepted the regulatory application by Swiss drug major Novartis’ generics unit Sandoz, for a biosimilar version of Amgen's Enbrel (etanercept). 2 October 2015
Late stage trials for by Anglo-Swedish drug major AstraZeneca’s brodalumab, to treat moderate to severe psoriasis, have shown positive results, according to a report published by the New England Journal of Medicine (NEJM). 1 October 2015
XenoPort had a roller-coaster morning after it announced positive preliminary top-line results from its Phase II clinical trial of XP23829 as a potential treatment for moderate-to-severe chronic plaque-type psoriasis. 15 September 2015
The atopic dermatitis (AD) market is on track to reach $16.7 billion across mature markets by 2030, according to data and analytics company GlobalData. 19 September 2024
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Danish dermatology specialist LEO Pharma has presented a range of new population-level and physician-reported data on the prevalence, severity and treatment of moderate to severe chronic hand eczema (CHE). 5 September 2024
Biocon Biologics has signed a settlement and license agreement with Johnson & Johnson that clears the way to commercialize its Bmab 1200, a proposed biosimilar to Stelara (ustekinumab), in Europe, the UK, Canada, and Japan. 3 September 2024
South Korea’s Celltrion yesterday announced the European Commission (EC) approval for the use of SteQeyma (CT-P43), an ustekinumab biosimilar referencing Stelara, for the treatment of multiple chronic inflammatory diseases. 27 August 2024
Danish dermatology specialist LEO Pharma’s Timber Pharmaceuticals subsidiary has announced disappointing results for the randomized, double-blind 12-week period of the ASCEND trial. 23 August 2024
San Diego, USA-based biotech AnaptysBio (Nasdaq: ANAB) yesterday announced the pricing of an underwritten offering of 2,750,498 shares of its common stock at a price of $36.50 per share, representing a premium of approximately 10% to Anaptys’ closing price on August 13, 2024. 15 August 2024
Shares of American dermatology company Verrica Pharmaceuticals had a roller-coaster start to the day after announcing what it called positive trial results. 14 August 2024
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
The US subsidiary of South Korea’s Celltrion announced its US Food and Drug Administration (FDA)-approved biosimilar adalimumab-aaty has been added to the Costco member prescription program. 14 August 2024
Crown Laboratories, a privately held skincare company, and Nashville, USA-based Revance Therapeutics have entered into an agreement whereby the companies seek to merge the two complementary organizations. 13 August 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
California’s Arcutis Biotherapeutics, a biopharma developing innovations in immuno-dermatology, has announced the US commercial launch of Zoryve (roflumilast) cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age six years. 30 July 2024
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended seven novel medicines for approval at its July 2024 meeting. 26 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024